Antitumor activity of XR5944, a novel and potent topoisomerase poison

Anti-cancer Drugs
A J StewartP A Charlton

Abstract

Inhibitors of topoisomerases are widely used in the treatment of cancer, including inhibitors of topoisomerase I (camptothecin analogs such as irinotecan and topotecan) and topoisomerase II (etoposide and doxorubicin). The novel bis-phenazine, XR5944, is a joint inhibitor of topoisomerase I and II as shown by the stabilization of topoisomerase-dependent cleavable complexes. XR5944 demonstrated exceptional activity against human and murine tumor cells in vitro and in vivo. In a range of cell lines XR5944 (IC50 0.04-0.4 nM) was significantly more potent than TAS-103, originally proposed as a joint topoisomerase I and II inhibitor, as well as agents specific for topoisomerase I or II (topotecan, doxorubicin and etoposide). In addition, XR5944 was unaffected by atypical drug resistance and retained significant activity in cells overexpressing P-glycoprotein or multidrug resistance-associated protein. Antitumor efficacy of XR5944 was demonstrated in human carcinoma xenograft models (H69 small cell lung cancer and HT29 colon). In the HT29 model, which is relatively unresponsive to chemotherapy, XR5944 (15 mg/kg i.v., q4dx3) induced tumor regression in the majority of animals (six of eight), whereas TAS-103, dosed at its maximum toler...Continue Reading

References

Apr 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G J FinlayB C Baguley
Aug 1, 1996·British Journal of Cancer·J Dancey, E A Eisenhauer
Jan 1, 1996·Annual Review of Biochemistry·J C Wang
Jan 1, 1997·British Journal of Cancer·P A Vasey, S B Kaye
Sep 28, 1998·Biochimica Et Biophysica Acta·K R Hande
Sep 28, 1998·Biochimica Et Biophysica Acta·S H Kaufmann
Jul 3, 1999·Japanese Journal of Cancer Research : Gann·Y AoyagiY Yamada

❮ Previous
Next ❯

Citations

Aug 6, 2008·Cancer Chemotherapy and Pharmacology·Andrew G JobsonCaroline A Austin
Oct 17, 2002·Journal of Molecular Biology·Susana C M TeixeiraChristine J Cardin
Dec 17, 2002·Critical Reviews in Oncology/hematology·Christian Bailly
May 3, 2012·Medicinal Research Reviews·Chung-Hang LeungDik-Lung Ma
Jul 14, 2009·Journal of Experimental & Clinical Cancer Research : CR·Erin R GardnerAlex Sparreboom
Dec 13, 2006·Anti-cancer Drugs·Louisa J LewisHelen M Coley
Jul 3, 2010·Organic & Biomolecular Chemistry·Claire SeillanOlivier Siri
Feb 18, 2012·Natural Product Reports·A CimminoR Kiss
Oct 1, 2004·Anti-cancer Drugs·Federica Di NicolantonioIan A Cree
Aug 20, 2004·The Journal of Biological Chemistry·Jixun DaiDanzhou Yang
Jul 1, 2009·American Journal of Pharmaceutical Education·Michael A Crouch
Oct 16, 2014·Dalton Transactions : an International Journal of Inorganic Chemistry·Kejie DuHui Chao
Jan 16, 2007·Molecular Cancer Therapeutics·Chandanamali PunchihewaDanzhou Yang
Aug 12, 2005·Molecular Cancer Therapeutics·Sarah A ByersDavid H Price
Mar 11, 2004·Chemical Reviews·Jane Buus Laursen, John Nielsen
May 6, 2021·Nucleic Acids Research·Melissa F AdasmeMichael Schroeder
Jul 25, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Adam J BuricDanzhou Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.